Clinical trials: Lymphoma, Hodgkins
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
This phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works in treating patients with…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High-Grade B-Cell Lymphoma
- Trial name
- NCT07098364
- Testing
- Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01505712
- Testing
- gene expression analysis, laboratory biomarker analysis
- Volunteers
- 393 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of combining thalidomide with interferon alfa in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT00015912
- Testing
- recombinant interferon alfa, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Hodgkin Disease
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
- Trial name
- NCT00540007
- Testing
- Lenalidomide
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Washington University School of Medicine
Classical Hodgkin Lymphoma
A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
This is a multicenter, open-label single-arm phase II study to evaluate the efficacy and safety of Zimberelimab (GLS-010) combined with AVD for newly diagnosed early-stage Hodgkin's lymphoma under the guidance of PET/CT.
- Trial name
- NCT05900765
- Testing
- Zimberelimab 240mg
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma.
- Trial name
- OLYMPIA-2 (NCT06097364)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 733 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma, Small Intestine Cancer
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003993
- Testing
- aldesleukin, bryostatin 1
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute on Aging (NIA)
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00453206
- Testing
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
The primary objective of this research study is to determine the maximum tolerated dose (MTD) of Ruxolitinib (Jakafi) in combination with standard dose Bortezomib (Velcade) in patients with relapsed or refractory Hodgkin (HL) and…
- Trial name
- NCT02613598
- Testing
- Bortezomib, Ruxolitinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan Rogel Cancer Center
HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD).
- Conditions
- HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT07793006
- Testing
- Lymph Node or Core Needle Biopsy, Fine Needle Aspiration, Tiny Isothermal Nucleic acid Amplification System (TINY)
- Where
- Malawi
- Volunteers
- 500 people
- Sponsor
- Indiana University
Non-Hodgkin's Lymphoma
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed…
- Trial name
- NCT03074825
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Multiple Myeloma, Non-Hodgkin Lymphoma
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia
- Trial name
- NCT01343368
- Testing
- Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cancer, Neuroendocrine Tumors
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid…
- Conditions
- Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma
- Trial name
- NCT01262235
- Testing
- TKM-080301
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Arbutus Biopharma Corporation
Childhood Cancer
Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients
Reduced activity levels and reduced muscular strength could severely impair the activities of daily living (ADLs) in pediatric leukemia and Non-Hodgkin lymphoma patients.
- Trial name
- NCT03934060
- Testing
- Exercise
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Technical University of Munich
Cancer, Cancer Metastatic
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors.
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer
- Trial name
- NCT05131815
- Testing
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
This phase I trial finds the appropriate parsaclisib dose level in combination with romidepsin for the treatment of T-cell lymphomas that have come back (relapsed) or that have not responded to standard treatment (refractory).
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Mycosis Fungoides
- Trial name
- NCT04774068
- Testing
- Parsaclisib, Romidepsin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Walter Hanel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.